CELGENE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,00...
May 28 2018 - 10:50PM
Business Wire
ClaimsFiler, a FREE shareholder information service, reminds
investors that they have only until May 29, 2018 to file
lead plaintiff applications in a securities class action lawsuit
against Celgene Corporation (NasdaqGS: CELG). Investor losses must
relate to purchases of the Company’s shares between January 12,
2015 and February 27, 2018. This action is pending in the United
States District Court for the District of New Jersey.
Get Help
Celgene investors should visit us at
https://www.claimsfiler.com/cases/view-celgene-corporation-securities-litigation
or call to speak to our claim center toll-free at (844)
367-9658.
About the Lawsuit
On February 27, 2018, the Company revealed that the U.S. Food
and Drug Administration had issued a refusal-to-file letter
rejecting the New Drug Application (“NDA”) for Ozanimod, one of its
leading drug candidates, because “the nonclinical and clinical
pharmacology sections in the NDA were insufficient to permit a
complete review.” On this news, the price of Celgene’s shares
plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information
source to help retail investors recover their share of billions of
dollars from securities class action settlements. ClaimsFiler's
team of experts monitor the securities class action landscape and
cull information from a variety of sources to ensure comprehensive
coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180528005368/en/
ClaimsFilerJerry Gallo,
844-367-9658https://www.claimsfiler.com
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jul 2023 to Jul 2024